StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
HSBC Downgrades Moderna (MRNA) to Reduce, 'INT marches on but RSV alerts'
February 26, 2024 2:48 AM
(Updated - February 26, 2024 4:23 AM EST)
HSBC analyst Yifeng Liu downgraded Moderna (NASDAQ: MRNA) from Hold to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
Moderna (MRNA) downgraded as HSBC skeptical on medium term INT Phase 3 data readouts
February 26, 2024 9:33 AM
Form S-8 Moderna, Inc.
February 23, 2024 4:24 PM
Form 10-K Moderna, Inc. For: Dec 31
February 23, 2024 4:06 PM
Form 4 Moderna, Inc. For: Feb 22 Filed by: Hoge Stephen
February 23, 2024 4:05 PM
Moderna's CMV trial offers further upside - UBS
February 23, 2024 9:39 AM
Moderna (MRNA) PT Lowered to $89 at Morgan Stanley
February 23, 2024 8:54 AM
Moderna (MRNA) PT Raised to $91 at Canaccord Genuity
February 23, 2024 7:13 AM
Form 144 Moderna, Inc. Filed by: Hoge Stephen
February 22, 2024 3:40 PM
Midday movers: Nvidia, Moderna rise; Etsy, Rivian fall
February 22, 2024 8:17 AM
Moderna fourth-quarter revenue beats estimates
February 22, 2024 6:58 AM
Moderna (MRNA) Tops Q4 EPS by $1.54, Beats on Revenue, Reaffirms COVID-19 Vax Guidance
February 22, 2024 6:46 AM
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
February 22, 2024 6:42 AM
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
February 22, 2024 6:41 AM
